Design of clinical trials in advanced prostate cancer: Avoiding the dead ends

BJU International, Supplement

Volumn 96, Issue 2, 2005, Pages 47-53

  Debruyne, Frans M J ^a   Watson, Kenneth ^b   Petrylak, Daniel ^c   Isaacs, John T ^d   Fitzpatrick, John ^e   Abrams, Paul ^f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Yamanouchi Group Business LLC   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

Author keywords

Clinical trials; Prostate cancer; Prostate cancer treatment

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; ZOLEDRONIC ACID;

ADVANCED CANCER; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG USE; EVALUATION; FUNDING; GOVERNMENT; HUMAN; INVESTMENT; METHODOLOGY; MONEY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; REGISTRATION; SAFETY;

CLINICAL TRIALS; DATA COLLECTION; HUMANS; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS;

EID: 29944443428     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05947.x     Document Type: Conference Paper

References (12)

1. Leaf C. Why we're losing the war on cancer (and how to win it). Fortune 2004; 149:76-82,84-6, 88-90
2. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004; 14: 143-9
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research. International Conference on Harmonization. Guidance for Industry: E6 Good Clinical Practice: Consolidated Guideline. April 1996. Available at: http://www.fda.gov/oc/gcp/guidance.html and http://www.fda.gov/cder/guidance/ 959fnl.pdf. Accessed September 2005
4. European Organisation for Research and Treatment of Cancer (EORTC). Guideline for Good Clinical Practice. Available at http://www.eortc.be/Services/ Doc/ICH_GCP.pdf. Accessed September 2005
5. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
6. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
7. European Organisation for Research and Treatment of Cancer (EORTC). Phase III comparison of early vs delayed endocrine manipulation (orchiectomy or LHRH agonist therapy) in previously untreated patients with nonmetastatic asymptomatic carcinoma of the prostate. Available at: http://www.cancer.gov/ clinicaltrials/EORTC-30891 or CDR0000075966. Accessed September 2005
8. Tannock IF, Osoba D, Stockier MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64
9. Smith PH, Bono A, Calais da Silva F et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC Trial 30853. The EORTC Urological Group. Cancer 1990; 66 (Suppl. 5): 1009-16
10. Debruyne FJ, Murray R, Fradet Y et al. for the Liarozole Study Group. Liarozole - a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Urology 1998; 52: 72-81
11. FDA Advisory Committee. Prostate cancer trials could use composite PSA/bone scan endpoint, PDA's Hirschfield says [press advisory] June 24, 2004. Available at: http://www.fdaadvisorycommittee. com/FDC/AdvisoryCommittee/ Stories/0621-2204_ProstateR.htm. Accessed September 2005
12. ZEUS Investigators. ZEUS study. Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patients. Eur Urol Today 2004; 16: Available at: http://www.uroweb.nl/files/uploaded_files/ EUT%202004%20JUN.pdf. Accessed September 2005